Andrew Fensome

Publications by Year

Research Areas

Estrogen and related hormone effects, Bioactive Compounds and Antitumor Agents, Cytokine Signaling Pathways and Interactions, Endometriosis Research and Treatment, Reproductive System and Pregnancy

Most-Cited Works

• → Design, Synthesis, and SAR of New Pyrrole-Oxindole Progesterone Receptor Modulators Leading to 5-(7-Fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348)(2008)196 cited
• → Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)(2018)170 cited
• → Potent nonsteroidal progesterone receptor agonists: Synthesis and SAR study of 6-aryl benzoxazines(2002)116 cited
• → 6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: A Novel Class of Potent, Selective, and Orally Active Nonsteroidal Progesterone Receptor Antagonists(2002)106 cited
• → Synthesis and Structure−Activity Relationship of Novel 6-Aryl-1,4- dihydrobenzo[d][1,3]oxazine-2-thiones as Progesterone Receptor Modulators Leading to the Potent and Selective Nonsteroidal Progesterone Receptor Agonist Tanaproget(2005)91 cited
• → The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis(2017)91 cited
• → Molecular and Pharmacological Properties of a Potent and Selective Novel Nonsteroidal Progesterone Receptor Agonist Tanaproget(2005)76 cited
• → Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases(2020)73 cited
• → New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles(2002)73 cited
• → Novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists(2003)61 cited